| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPL22 |
| Uniprot No | P35268 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-128aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMAPVKKL VVKGGKKKKQ VLKFTLDCTH PVEDGIMDAA NFEQFLQERI KVNGKAGNLG GGVVTIERSK SKITVTSEVP FSKRYLKYLT KKYLKKNNLR DWLRVVANSK ESYELRYFQI NQDEEEEEDE D |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPL22重组蛋白的3篇参考文献示例(部分信息为模拟整理)：
---
1. **文献名称**: *RPL22 regulates the development of γδ T cells through protein translation*
**作者**: Chen J, et al.
**摘要**: 研究揭示了RPL22通过调控特定mRNA的翻译效率，影响γδ T细胞的分化与功能，其重组蛋白的体外实验表明其与T细胞受体信号通路的相互作用。
2. **文献名称**: *RPL22 loss impairs ribosome localization key for leukemia suppression*
**作者**: Rao S, et al.
**摘要**: 发现RPL22缺失通过扰乱核糖体定位，导致异常蛋白翻译，促进白血病进展;重组RPL22的导入可部分恢复核糖体功能并抑制肿瘤生长。
3. **文献名称**: *Structural basis of RPL22 interaction with viral RNA in antiviral immunity*
**作者**: Kim H, et al.
**摘要**: 通过重组RPL22蛋白的晶体结构分析，揭示了其RNA结合域与特定病毒RNA的互作机制，为抗病毒免疫应答提供了分子机制解释。
---
*注：以上文献信息为模拟示例，实际研究需通过PubMed/Google Scholar等平台检索真实论文。*
**Background of Recombinant RPL22 Protein**
RPL22 (ribosomal protein L22) is a component of the 60S ribosomal subunit, playing a critical role in mRNA translation and ribosome biogenesis. Beyond its canonical function in protein synthesis, RPL22 has garnered attention for its involvement in diverse cellular processes, including hematopoiesis, immune regulation, and tumor suppression. Studies reveal that RPL22 can act as a haploinsufficient tumor suppressor, particularly in hematopoietic malignancies, where its loss or mutation correlates with disease progression.
Recombinant RPL22 protein is engineered using heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*) to produce purified, functional RPL22 for research applications. This recombinant form enables detailed studies of its molecular interactions, such as binding to specific RNA motifs or regulatory proteins like p53. which is critical for understanding its role in apoptosis and cell cycle control. Additionally, recombinant RPL22 facilitates structural analyses (e.g., X-ray crystallography or cryo-EM) to elucidate its conformational dynamics within ribosomes or extra-ribosomal complexes.
Emerging research highlights RPL22's involvement in immune responses, including modulating T-cell development and viral infection responses, suggesting therapeutic potential. Recombinant RPL22 also serves as a tool to investigate its aberrant expression in cancers, offering insights into diagnostic or prognostic biomarkers. By leveraging recombinant technology, researchers aim to decode RPL22's dual roles in ribosome function and disease pathogenesis, bridging gaps between basic biology and clinical applications.
×
